舍曲林有助于急性心肌梗塞后抑郁患者的心脏康复
WESTPORT, CT (Reuters Health) - Treatment of depressed patients with the selective serotonin reuptake inhibitor sertraline appears to facilitate recovery of cardiac autonomic function after acute myocardial infarction (MI), according to Canadian researchers.
Dr. Allan McFarlane, and colleagues at McMaster University Faculty of Health Sciences in Hamilton, Ontario, note that "depressed patients having an acute myocardial infarction are particularly predisposed to major adverse outcomes within the first year of the acute event."
To determine whether sertraline treatment might be helpful in avoiding such consequences, the researchers studied 38 post-MI depressed patients and a reference group of 11 post-MI stable nondepressed patients. The findings appeared in the October issue of the American Heart Journal.
Subjects with depression were randomized to treatment with sertraline 50 mg per day or placebo. Among parameters measured during the 6-month study was the rate of recovery of heart rate variability. This was determined by analysis of the SD of 24-hour N-N intervals (SDNN) which, say the investigators is "a potent predictor of cardiac mortality."
In the sertraline-treated group, there was a linear increase in SDNN which paralleled that in the reference group. In the placebo group, there was "a modest but significant decline" in SDNN from weeks 2 to 22.
In light of these findings, the researchers conclude that the use of selective serotonin reuptake inhibitors in depressed post-MI patients is "worthy of being tested in larger and longer-term clinical trials."
Commenting on the results, Dr. McFarlane told Reuters Health that they "suggest an interaction between depressed mood and the brain's control of important aspects of heart functioning." This interaction, he added, "draws our attention back to mind-body relationships and the importance of treatment of the whole human being.", http://www.100md.com
Dr. Allan McFarlane, and colleagues at McMaster University Faculty of Health Sciences in Hamilton, Ontario, note that "depressed patients having an acute myocardial infarction are particularly predisposed to major adverse outcomes within the first year of the acute event."
To determine whether sertraline treatment might be helpful in avoiding such consequences, the researchers studied 38 post-MI depressed patients and a reference group of 11 post-MI stable nondepressed patients. The findings appeared in the October issue of the American Heart Journal.
Subjects with depression were randomized to treatment with sertraline 50 mg per day or placebo. Among parameters measured during the 6-month study was the rate of recovery of heart rate variability. This was determined by analysis of the SD of 24-hour N-N intervals (SDNN) which, say the investigators is "a potent predictor of cardiac mortality."
In the sertraline-treated group, there was a linear increase in SDNN which paralleled that in the reference group. In the placebo group, there was "a modest but significant decline" in SDNN from weeks 2 to 22.
In light of these findings, the researchers conclude that the use of selective serotonin reuptake inhibitors in depressed post-MI patients is "worthy of being tested in larger and longer-term clinical trials."
Commenting on the results, Dr. McFarlane told Reuters Health that they "suggest an interaction between depressed mood and the brain's control of important aspects of heart functioning." This interaction, he added, "draws our attention back to mind-body relationships and the importance of treatment of the whole human being.", http://www.100md.com